Published 23 days ago • loading... • Updated 21 days ago
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
Zhejiang Wenda Pharmaceutical Technology Co., Ltd. will present Phase II data for oral BET inhibitor NHWD-870 HCl in Chinese patients with advanced NUT carcinoma at the 2026 ESMO Annual Meeting.
In the multicenter, open-label trial, patients received 2 mg of NHWD-870 HCl orally for five days, followed by two days off, in 28-day cycles.
An independent review found an objective response rate of 30.0% and a disease control rate of 47.5% among 40 patients.
Median progression-free survival was 2.76 months and overall survival was 9.33 months; the response rate among patients with primary thoracic tumors was 45.0%.